<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">A significant number of those diagnosed with COVID-19 have reported a broad spectrum of neurological consequences
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>–
  <xref ref-type="bibr" rid="CR32">32</xref>
 </sup>. Neurological symptoms include those associated with dysfunction of the central (fatigue, headache, confusion, stroke
 <sup>
  <xref ref-type="bibr" rid="CR33">33</xref>
 </sup>, dizziness, syncope
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>
 </sup>, seizure, anorexia, and insomnia)
 <sup>
  <xref ref-type="bibr" rid="CR35">35</xref>–
  <xref ref-type="bibr" rid="CR38">38</xref>
 </sup>, peripheral (anosmia, ageusia, myoclonus
 <sup>
  <xref ref-type="bibr" rid="CR39">39</xref>
 </sup>, neuropathic pain, and myalgias)
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>,
  <xref ref-type="bibr" rid="CR35">35</xref>,
  <xref ref-type="bibr" rid="CR40">40</xref>
 </sup>, combined central-peripheral (Guillain Barre syndrome
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup>) and enteric nervous systems (diarrhea
 <sup>
  <xref ref-type="bibr" rid="CR13">13</xref>
 </sup>). Some gastrointestinal manifestations, including diarrhea, may be related to the expression of the viral receptor ACE2 and a serine protease, transmembrane serine protease 2 (TMPRSS2), involved in S protein priming, in the small intestinal epithelia and colon
 <sup>
  <xref ref-type="bibr" rid="CR42">42</xref>
 </sup>.
</p>
